Technical analysis of Kazia Therapeutics Ltd ADR (KZIA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous...
Price Performance
| 1 month | -29.07% |
| 3 months | -26.41% |
| Year-to-date | +48.04% |
| 1 year | +28.46% |
| 3 years | -79.60% |
| 5 years | -98.12% |
52-Week Range
| 52-week High | $17.40 |
| 52-week Low | $4.86 |
| Avg Volume (90d) | 230K |
Technical Indicators
| SMA 50 | $12.97 |
| SMA 200 | $10.62 |
| Beta | 1.62 |
| 30-day Volatility (annualised) | 102.1% |
| Price vs SMA 50 | -21.4% |
| Price vs SMA 200 | -3.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $7.81 | |
| 2025-11 | $10.55 | +35.1% |
| 2025-12 | $6.89 | -34.7% |
| 2026-01 | $5.86 | -14.9% |
| 2026-02 | $8.45 | +44.2% |
| 2026-03 | $7.44 | -12.0% |
| 2026-04 | $13.64 | +83.3% |
| 2026-05 | $12.78 | -6.3% |
| 2026-06 | $14.08 | +10.2% |
| 2026-07 | $12.62 | -10.4% |
| 2026-08 | $13.77 | +9.1% |
| 2026-09 | $10.20 | -25.9% |
Price
| Price | $10.20 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | AU |
Valuation Ratios
| Price / Book | 0.95 |
| EV / EBITDA | 2.30 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.87 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -40.25 |